Amicus Therapeutics Inc
Most Recent
Here Are Amicus’s Key Research Programs in 2019
Amicus Therapeutics is targeting a market opportunity worth more than $1.0 billion to $2.0 billion with its investigational AT-GAA ERT in the Pompe disease indication.
How Is Amicus Therapeutics’ Galafold Placed in the First Quarter?
According to the first-quarter earnings conference call, Amicus Therapeutics doesn’t expect linear revenue growth for Galafold on a quarter-over-quarter basis.
FOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019
Analysts expect Amicus Therapeutics’ revenues to rise YoY by 89.66% to $173.05 million in fiscal 2019.
What Are Analysts Recommending for FOLD and PTLA in May?
Amicus Therapeutics and Portola Pharmaceuticals both have a consensus “buy” rating in May.
How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
Jazz Pharmaceuticals: Analysts’ View in November
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.
Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.
Analyzing PTC Therapeutics’ Performance in September
On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.
Analyzing Audentes Therapeutics’ Valuation Metrics
Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with $22.74 million in Q2 2017.
How Analysts View Amicus Therapeutics in September
Amicus Therapeutics (FOLD) plans to start the pivotal trial for AT-GAA in the second half of 2018.
Why Amicus Therapeutics Stock Rose Last Week
Amicus Therapeutics (FOLD) saw a 19% rise in its stock in the week ended May 18.
Analyzing the Market Potential for Amicus’s Galafold
According to Amicus Therapeutics, the annual incidence of the disease in newborn males is estimated to be between 1:40,000 and 1:60,000.
Exploring Amicus Therapeutics’ Promising Research Pipeline
Amicus Therapeutics’ most recent novel proprietary enzyme replacement therapy is currently in late preclinical development.
Analysts Rate Voyager Therapeutics and Its Peers in April
Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.
Why Amicus Therapeutics Stock Rose in the Week Ended March 29
On March 29, 2018, Amicus Therapeutics (FOLD) was trading at $15.04, which represented a ~135% rise from its 52-week low of $6.41.
IBB Small-Caps Reduce Negative Returns in December
The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.